Cardiovascular Drugs market
Global Cardiovascular Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Cardiovascular drugs are agents used for the treatment of diseases associated with the circulatory system, which include blood clots, stroke, coronary artery disease, variation in blood pressure, arrhythmias, high cholesterol, and heart failure. Increasing aging population, increasing prevalence of cardiovascular diseases, high incidence of obesity, and an unhealthy lifestyle are driving the demand for cardiovascular drugs. Complex drug development process and adverse effects of cardiovascular drugs are hampering the growth of the market. There is a constant increase in the incidence of cardiovascular diseases. According to WHO, in 2015, approximately 17.7 million people died due to various cardiovascular diseases. Increase in expenditure for R&D of novel cardiovascular drugs and increased government initiatives to raise the alertness of different types of cardiovascular conditions are expected to drive the market growth. Additionally, variation in lifestyle has increased the prevalence of the obesity, which has further led to the increase in the incidence of cardiovascular disorders globally. Nevertheless, the rigorous regulatory approval process for drugs, high treatment cost, and side effects related to cardiovascular drugs are hindering the progress of the market.
Market Analysis: The global cardiovascular drugs market is estimated to witness a CAGR of 2.8% during the forecast period 2018–2024. The market is analyzed based on two segments: product types and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on types, the market is segmented into anti-hypertensives, anti-hyperlipidemics, anticoagulants, antiarrhythmics, and others. Cardiac glycosides, antianginal drugs, anti-fibrinolytic, and anti-ischemic drugs are the other key product types in the market. The market is dominated by anti-hypertensives.
Key Players: Novartis AG, Sanofi, Bayer AG, Johnson & Johnson, Astra Zeneca PLC, and Pfizer are the key players in the market. The other prominent players in the market include Daiichi Sankyo, Inc., Bristol–Myers Squibb, GlaxoSmithKline plc, United Therapeutics Corp., Sun Pharmaceuticals, Eli Lilly and Company, Takeda Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, and Gilead Sciences, Inc.
Competitive Analysis: Mergers & acquisitions, approval of new drugs, and product launch are the primary strategies followed by various players in the market to increase their revenue. In March 2017, Espero Pharmaceuticals, Inc., a privately held company in commercial-stage cardiovascular pharmaceutical and Armetheon, Inc., a private company in late-clinical stage pharmaceutical have planned to merge. J&J, a major company in the cardiovascular drugs market established its footprints in this sector in 2008 with the approval of Xarelto in the US. Currently, in 2016, Xarelto earned revenue of ~$2.5 billion and is anticipated to rise to ~$3.5 billion by 2024. In January 2017, J&J acquired Actelion and added Uptravi & Opsumit to its portfolio, which are expected to secure the market leadership of the company. Warfarin by Epocrates, Inc. is struggling to maintain the market share from a stable rivulet of new products such as Xarelto, Pradaxa, Eliquis, and Savaysa.
Benefits: The report provides complete details about the usage and adoption rate of cardiovascular drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
Overview: Cardiovascular drugs are agents used for the treatment of diseases associated with the circulatory system, which include blood clots, stroke, coronary artery disease, variation in blood pressure, arrhythmias, high cholesterol, and heart failure. Increasing aging population, increasing prevalence of cardiovascular diseases, high incidence of obesity, and an unhealthy lifestyle are driving the demand for cardiovascular drugs. Complex drug development process and adverse effects of cardiovascular drugs are hampering the growth of the market. There is a constant increase in the incidence of cardiovascular diseases. According to WHO, in 2015, approximately 17.7 million people died due to various cardiovascular diseases. Increase in expenditure for R&D of novel cardiovascular drugs and increased government initiatives to raise the alertness of different types of cardiovascular conditions are expected to drive the market growth. Additionally, variation in lifestyle has increased the prevalence of the obesity, which has further led to the increase in the incidence of cardiovascular disorders globally. Nevertheless, the rigorous regulatory approval process for drugs, high treatment cost, and side effects related to cardiovascular drugs are hindering the progress of the market.
Market Analysis: The global cardiovascular drugs market is estimated to witness a CAGR of 2.8% during the forecast period 2018–2024. The market is analyzed based on two segments: product types and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share, followed by Europe, Asia Pacific, and Rest of the World. More than 60% of the market is occupied by North America, with the US being the major contributor to the market growth.
Product Analysis: Based on types, the market is segmented into anti-hypertensives, anti-hyperlipidemics, anticoagulants, antiarrhythmics, and others. Cardiac glycosides, antianginal drugs, anti-fibrinolytic, and anti-ischemic drugs are the other key product types in the market. The market is dominated by anti-hypertensives.
Key Players: Novartis AG, Sanofi, Bayer AG, Johnson & Johnson, Astra Zeneca PLC, and Pfizer are the key players in the market. The other prominent players in the market include Daiichi Sankyo, Inc., Bristol–Myers Squibb, GlaxoSmithKline plc, United Therapeutics Corp., Sun Pharmaceuticals, Eli Lilly and Company, Takeda Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, and Gilead Sciences, Inc.
Competitive Analysis: Mergers & acquisitions, approval of new drugs, and product launch are the primary strategies followed by various players in the market to increase their revenue. In March 2017, Espero Pharmaceuticals, Inc., a privately held company in commercial-stage cardiovascular pharmaceutical and Armetheon, Inc., a private company in late-clinical stage pharmaceutical have planned to merge. J&J, a major company in the cardiovascular drugs market established its footprints in this sector in 2008 with the approval of Xarelto in the US. Currently, in 2016, Xarelto earned revenue of ~$2.5 billion and is anticipated to rise to ~$3.5 billion by 2024. In January 2017, J&J acquired Actelion and added Uptravi & Opsumit to its portfolio, which are expected to secure the market leadership of the company. Warfarin by Epocrates, Inc. is struggling to maintain the market share from a stable rivulet of new products such as Xarelto, Pradaxa, Eliquis, and Savaysa.
Benefits: The report provides complete details about the usage and adoption rate of cardiovascular drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry Overview
1.2 Industry Trends
1.3 Total Addressable Market (TAM)
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.2.1 Trends of cardiovascular drugs market
3.3 Related Markets
3.3.1 Oncology (Cancer) Drugs
3.3.2 Active pharmaceutical ingredients (APIs)
3.3.3 Over the counter drugs (OTC)
3.3.4 Diabetes Drugs
4 MARKET OUTLINE
4.1 Cardiovascular Drugs Approved by FDA (2011 – 2016)
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing Aging Population
5.1.1.2 Increasing prevalence of cardiovascular diseases
5.1.1.3 High Prevalence of Obesity
5.1.1.4 Unhealthy lifestyle
5.1.2 Opportunities
5.1.2.1 Increase merger and acquisitions
5.1.3 Restraints
5.1.3.1 Complex drug development process
5.1.3.2 Adverse effects of cardiovascular drugs
5.1.4 DRO – Impact Analysis
5.1.5 Key Stakeholders
6 PRODUCT TYPE: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Anti-Hypertensives
6.3 Anti-Hyperlipidemics
6.4 Anti-Coagulants
6.5 Anti-Arrhythmic
6.6 Others
7 REGIONS: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 North America
7.2.1 Overview
7.2.2 United States
7.2.3 Canada
7.3 Europe
7.3.1 Overview
7.3.2 United Kingdom
7.3.3 Germany
7.4 APAC
7.4.1 Overview
7.4.2 India
7.4.3 China
7.4.4 Japan
7.5 Rest of the World
7.5.1 Overview
7.5.2 Africa
7.5.3 Brazil
8 COMPETITIVE LANDSCAPE
9 VENDOR PROFILES
9.1 Novartis AG
9.1.1 Overview
9.1.2 Business Unit
9.1.3 Geographic Presence
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategy
9.2 Sanofi
9.2.1 Overview
9.2.2 Geographic Revenue
9.2.3 Business Focus
9.2.4 SWOT Analysis
9.2.5 Business Strategy
9.3 Bayer AG
9.3.1 Overview
9.3.2 Business Unit
9.3.3 Geographic Presence
9.3.4 Business Focus
9.3.5 SWOT Analysis
9.3.6 Business Strategy
9.4 Johnson & Johnson
9.4.1 Overview
9.4.2 Business Units
9.4.3 Geographic Revenue
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategies
9.5 Astra Zenca PLC.
9.5.1 Overview
9.5.2 Geographic Presence
9.5.3 Business Focus
9.5.4 SWOT Analysis
9.5.5 Business Strategy
10 COMPANIES TO WATCH FOR
10.1 Daiichi Sankyo, Inc.
10.1.1 Overview
10.1.2 Overview
10.2 Bristol-Myers Squibb
10.2.1 Overview
10.3 GlaxoSmithKline plc
10.3.1 Overview
10.4 United Therapeutics Corp
10.4.1 Overview
10.4.2 Highlights
10.5 Sun Pharmaceuticals.
10.5.1 Overview
10.5.2 Highlights
10.6 Eli Lilly and Company.
10.6.1 Overview
10.7 Takeda Pharmaceutical Co, Ltd
10.7.1 Overview
10.7.2 Highlights:
10.8 Boehringer Ingelheim GmbH
10.8.1 Overview
10.8.2 Highlights:
10.9 Gilead Sciences, Inc
10.9.1 Overview
10.9.2 Highlights:
Annexure
Abbreviations
Tables
Table 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY
Table 1 CARDIOVASCULAR DRUGS MARKET REVENUE BY TYPES, 2017–2024 ($BILLION)
Table 2 CARDIOVASCULAR DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($BILLION)
Table 3 NOVARTIS AG: OFFERINGS
Table 4 NOVARTIS AG: RECENT DEVELOPMENTS
Table 5 SANOFI: OFFERINGS
Table 6 SANOFI: RECENT DEVELOPMENTS
Table 7 BAYER AG: OFFERINGS
Table 8 BAYER AG: RECENT DEVELOPMENTS
Table 9 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 10 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 11 ASTRA ZENCA PLC: OFFERINGS
Table 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS
Table 13 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS
Table 14 BRISTOL-MYERS SQUIBB.: RECENT DEVELOPMENTS
Table 15 BRISTOL-MYERS SQUIBB.: KEY DEVELOPMENTS
Table 16 GLAXOSMITHKLINE PLC.: OVERVIEW
Table 17 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 18 UNITED THERAPEUTICS CORP.: OVERVIEW
Table 19 SUN PHARMACEUTICALS: OVERVIEW
Table 20 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
Table 21 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW
Table 22 BOEHRINGER INGELHEIM GMBH: OVERVIEW
Table 23 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS
Table 24 GILEAD SCIENCES, INC.: OVERVIEW
?
Charts
Chart 1 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION)
Chart 2 RESEARCH METHODOLOGY OF GLOBAL CARDIOVASCULAR DRUGS MARKET
Chart 3 GLOBAL CARDIOVASCULAR DRUGS MARKET REVENUE, 2017-2024 ($BILLION)
Chart 4 NUMBER OF CARDIOVASCULAR DRUGS APPROVED FROM 2011-2016
Chart 5 SEGMENTATION OF GLOBAL CARDIOVASCULAR DRUGS MARKET
Chart 6 PORTER 5 FORCES OF CARDIOVASCULAR DRUGS MARKET
Chart 7 PEST ANALYSIS OF CARDIOVASCULAR DRUGS MARKET
Chart 8 MARKET DYNAMICS – DRO ANALYSIS
Chart 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)
Chart 10 DRO – IMPACT ANALYSIS OF GLOBAL CARDIOVASCULAR DRUGS MARKET
Chart 11 KEY STAKEHOLDERS
Chart 12 CARDIOVSCULAR DRUGS MARKET BY PRODUCT TYPE SEGMENTATION, 2017-2024 ($BILLION)
Chart 13 ANTI-HYPERTENSIVES CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 14 ANTI-HYPERLIPIDEMICS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 15 ANTI-COAGULANTS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 16 ANTI-ARRHYTHMIC CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 17 OTHERS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 18 CARDIOVASCULAR DISEASES PREVALENCE WORLDWIDE IN MILLIONS (2015)
Chart 19 CARDIOVACULAR DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)
Chart 20 CARDIOVASCULAR DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($BILLION)
Chart 21 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE EUROPE REGION, 2017–2023 ($BILLION)
Chart 22 TYPE OF MEDICATION USED BY ADULTS WITH CARDIOVASCULAR DISEASE IN THE UK IN 2014
Chart 23 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE APAC REGION, 2017–2023 ($BILLION)
Chart 24 CARDIOVASCULAR DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2023 ($BILLION)
Chart 25 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 26 NOVARTIS AG: BUSINESS UNITS
Chart 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE
Chart 28 NOVARTIS AG: SWOT ANALYSIS
Chart 29 SANOFI SA: OVERVIEW SNAPSHOT
Chart 30 SANOFI SA: SEGMENTATION
Chart 31 SANOFI SA: GEOGRAPHIC REVENUE
Chart 32 SANOFI SA: SWOT ANALYSIS
Chart 33 BAYER AG: OVERVIEW SNAPSHOT
Chart 34 BAYER AG: BUSINESS UNITS
Chart 35 BAYER GA: GEOGRAPHICAL PRESENCE
Chart 36 BAYER AG: SWOT ANALYSIS
Chart 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 38 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 39 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 40 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 41 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT
Chart 42 ASTRA ZENCA PLC: BUSINESS UNITS
Chart 43 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE
Chart 44 ASTRA ZENCA PLC: SWOT ANALYSIS
1.1 Industry Overview
1.2 Industry Trends
1.3 Total Addressable Market (TAM)
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.2.1 Trends of cardiovascular drugs market
3.3 Related Markets
3.3.1 Oncology (Cancer) Drugs
3.3.2 Active pharmaceutical ingredients (APIs)
3.3.3 Over the counter drugs (OTC)
3.3.4 Diabetes Drugs
4 MARKET OUTLINE
4.1 Cardiovascular Drugs Approved by FDA (2011 – 2016)
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 MARKET CHARACTERISTICS
5.1 Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing Aging Population
5.1.1.2 Increasing prevalence of cardiovascular diseases
5.1.1.3 High Prevalence of Obesity
5.1.1.4 Unhealthy lifestyle
5.1.2 Opportunities
5.1.2.1 Increase merger and acquisitions
5.1.3 Restraints
5.1.3.1 Complex drug development process
5.1.3.2 Adverse effects of cardiovascular drugs
5.1.4 DRO – Impact Analysis
5.1.5 Key Stakeholders
6 PRODUCT TYPE: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Anti-Hypertensives
6.3 Anti-Hyperlipidemics
6.4 Anti-Coagulants
6.5 Anti-Arrhythmic
6.6 Others
7 REGIONS: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 North America
7.2.1 Overview
7.2.2 United States
7.2.3 Canada
7.3 Europe
7.3.1 Overview
7.3.2 United Kingdom
7.3.3 Germany
7.4 APAC
7.4.1 Overview
7.4.2 India
7.4.3 China
7.4.4 Japan
7.5 Rest of the World
7.5.1 Overview
7.5.2 Africa
7.5.3 Brazil
8 COMPETITIVE LANDSCAPE
9 VENDOR PROFILES
9.1 Novartis AG
9.1.1 Overview
9.1.2 Business Unit
9.1.3 Geographic Presence
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategy
9.2 Sanofi
9.2.1 Overview
9.2.2 Geographic Revenue
9.2.3 Business Focus
9.2.4 SWOT Analysis
9.2.5 Business Strategy
9.3 Bayer AG
9.3.1 Overview
9.3.2 Business Unit
9.3.3 Geographic Presence
9.3.4 Business Focus
9.3.5 SWOT Analysis
9.3.6 Business Strategy
9.4 Johnson & Johnson
9.4.1 Overview
9.4.2 Business Units
9.4.3 Geographic Revenue
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategies
9.5 Astra Zenca PLC.
9.5.1 Overview
9.5.2 Geographic Presence
9.5.3 Business Focus
9.5.4 SWOT Analysis
9.5.5 Business Strategy
10 COMPANIES TO WATCH FOR
10.1 Daiichi Sankyo, Inc.
10.1.1 Overview
10.1.2 Overview
10.2 Bristol-Myers Squibb
10.2.1 Overview
10.3 GlaxoSmithKline plc
10.3.1 Overview
10.4 United Therapeutics Corp
10.4.1 Overview
10.4.2 Highlights
10.5 Sun Pharmaceuticals.
10.5.1 Overview
10.5.2 Highlights
10.6 Eli Lilly and Company.
10.6.1 Overview
10.7 Takeda Pharmaceutical Co, Ltd
10.7.1 Overview
10.7.2 Highlights:
10.8 Boehringer Ingelheim GmbH
10.8.1 Overview
10.8.2 Highlights:
10.9 Gilead Sciences, Inc
10.9.1 Overview
10.9.2 Highlights:
Annexure
Abbreviations
Tables
Table 1 TOP ACQUISITIONS IN CARDIOVASCULAR INDUSTRY
Table 1 CARDIOVASCULAR DRUGS MARKET REVENUE BY TYPES, 2017–2024 ($BILLION)
Table 2 CARDIOVASCULAR DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($BILLION)
Table 3 NOVARTIS AG: OFFERINGS
Table 4 NOVARTIS AG: RECENT DEVELOPMENTS
Table 5 SANOFI: OFFERINGS
Table 6 SANOFI: RECENT DEVELOPMENTS
Table 7 BAYER AG: OFFERINGS
Table 8 BAYER AG: RECENT DEVELOPMENTS
Table 9 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 10 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 11 ASTRA ZENCA PLC: OFFERINGS
Table 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS
Table 13 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS
Table 14 BRISTOL-MYERS SQUIBB.: RECENT DEVELOPMENTS
Table 15 BRISTOL-MYERS SQUIBB.: KEY DEVELOPMENTS
Table 16 GLAXOSMITHKLINE PLC.: OVERVIEW
Table 17 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 18 UNITED THERAPEUTICS CORP.: OVERVIEW
Table 19 SUN PHARMACEUTICALS: OVERVIEW
Table 20 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
Table 21 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW
Table 22 BOEHRINGER INGELHEIM GMBH: OVERVIEW
Table 23 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS
Table 24 GILEAD SCIENCES, INC.: OVERVIEW
?
Charts
Chart 1 GLOBAL CARDIOVASCULAR DISEASE MARKET 2017 ($BILLION)
Chart 2 RESEARCH METHODOLOGY OF GLOBAL CARDIOVASCULAR DRUGS MARKET
Chart 3 GLOBAL CARDIOVASCULAR DRUGS MARKET REVENUE, 2017-2024 ($BILLION)
Chart 4 NUMBER OF CARDIOVASCULAR DRUGS APPROVED FROM 2011-2016
Chart 5 SEGMENTATION OF GLOBAL CARDIOVASCULAR DRUGS MARKET
Chart 6 PORTER 5 FORCES OF CARDIOVASCULAR DRUGS MARKET
Chart 7 PEST ANALYSIS OF CARDIOVASCULAR DRUGS MARKET
Chart 8 MARKET DYNAMICS – DRO ANALYSIS
Chart 9 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960-2060 (%)
Chart 10 DRO – IMPACT ANALYSIS OF GLOBAL CARDIOVASCULAR DRUGS MARKET
Chart 11 KEY STAKEHOLDERS
Chart 12 CARDIOVSCULAR DRUGS MARKET BY PRODUCT TYPE SEGMENTATION, 2017-2024 ($BILLION)
Chart 13 ANTI-HYPERTENSIVES CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 14 ANTI-HYPERLIPIDEMICS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 15 ANTI-COAGULANTS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 16 ANTI-ARRHYTHMIC CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 17 OTHERS CARDIOVASCULAR DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 ($BILLION)
Chart 18 CARDIOVASCULAR DISEASES PREVALENCE WORLDWIDE IN MILLIONS (2015)
Chart 19 CARDIOVACULAR DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)
Chart 20 CARDIOVASCULAR DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 ($BILLION)
Chart 21 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE EUROPE REGION, 2017–2023 ($BILLION)
Chart 22 TYPE OF MEDICATION USED BY ADULTS WITH CARDIOVASCULAR DISEASE IN THE UK IN 2014
Chart 23 CARDIOVASCULAR DRUGS MARKET REVENUE IN THE APAC REGION, 2017–2023 ($BILLION)
Chart 24 CARDIOVASCULAR DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2023 ($BILLION)
Chart 25 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 26 NOVARTIS AG: BUSINESS UNITS
Chart 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE
Chart 28 NOVARTIS AG: SWOT ANALYSIS
Chart 29 SANOFI SA: OVERVIEW SNAPSHOT
Chart 30 SANOFI SA: SEGMENTATION
Chart 31 SANOFI SA: GEOGRAPHIC REVENUE
Chart 32 SANOFI SA: SWOT ANALYSIS
Chart 33 BAYER AG: OVERVIEW SNAPSHOT
Chart 34 BAYER AG: BUSINESS UNITS
Chart 35 BAYER GA: GEOGRAPHICAL PRESENCE
Chart 36 BAYER AG: SWOT ANALYSIS
Chart 37 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 38 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 39 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 40 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 41 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT
Chart 42 ASTRA ZENCA PLC: BUSINESS UNITS
Chart 43 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE
Chart 44 ASTRA ZENCA PLC: SWOT ANALYSIS
